Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
homochlorcyclizine
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Homochlorcyclizine is a first-generation antihistamine of the diphenylmethylpiperazine group, marketed in Japan since 1965 for the treatment of allergic conditions such as urticaria, allergic rhinitis, and pruritus associated with skin diseases (eczema, dermatitis). It acts primarily as a competitive antagonist at histamine H1 receptor, thereby inhibiting the effects of histamine in allergic responses. In addition to its antihistaminic activity, it exhibits antimuscarinic (anticholinergic), antidopaminergic, and antiserotonergic properties. Homochlorcyclizine also inhibits bradykinin-induced contractions and partially blocks slow-reacting substance of anaphylaxis (SRS-A)–induced contractions. The drug is administered orally and is known for sedative side effects typical of first-generation antihistamines[1][3][4][5][6][7][8].
- Other names
- homochlorcyclizinumhomoclorociclizina
02
Targets
DRD (Dopamine receptors)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on homochlorcyclizine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on homochlorcyclizine.